These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

39 related articles for article (PubMed ID: 17926208)

  • 21. [Troubling shortage of drugs].
    Kiefer B
    Rev Med Suisse; 2012 May; 8(342):1144. PubMed ID: 22734188
    [No Abstract]   [Full Text] [Related]  

  • 22. Access to life-saving medicines and intellectual property rights: an ethical assessment.
    Schroeder D; Singer P
    Camb Q Healthc Ethics; 2011 Apr; 20(2):279-89. PubMed ID: 21435303
    [No Abstract]   [Full Text] [Related]  

  • 23. Access before approval--a right to take experimental drugs?
    Okie S
    N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
    [No Abstract]   [Full Text] [Related]  

  • 24. Current status of orphan disease drug development.
    Thoene JG
    Curr Opin Pediatr; 1994 Apr; 6(2):209-12. PubMed ID: 8032402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physicians and Insider Trading.
    Kesselheim AS; Sinha MS; Joffe S
    JAMA Intern Med; 2015 Dec; 175(12):1955-9. PubMed ID: 26457747
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The ethical plausibility of the 'Right To Try' laws.
    Carrieri D; Peccatori FA; Boniolo G
    Crit Rev Oncol Hematol; 2018 Feb; 122():64-71. PubMed ID: 29458791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulatory oversight of cell therapy in China: Government's efforts in patient access and therapeutic innovation.
    Wu W; Wang Y; Tang Z; Gao Y; Huo Y
    Pharmacol Res; 2020 Aug; 158():104889. PubMed ID: 32428666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Accompanying patients in the arrival of new treatments. The AFM-Téléthon regional services experience - Clinical use of innovative, repurposed or off-label therapies: a real life experience (3)].
    Merret G
    Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():26-27. PubMed ID: 30943157
    [No Abstract]   [Full Text] [Related]  

  • 29. Access for the terminally ill to experimental medical innovations: a three-pronged threat.
    Bender S; Flicker L; Rhodes R
    Am J Bioeth; 2007 Oct; 7(10):3-6. PubMed ID: 17926208
    [No Abstract]   [Full Text] [Related]  

  • 30. Terminal illness and access to Phase 1 experimental agents, surgeries and devices: reviewing the ethical arguments.
    Schüklenk U; Lowry C
    Br Med Bull; 2009; 89():7-22. PubMed ID: 19056723
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expanding access to investigational new therapies.
    Cohen C; Shevitz A; Mayer K
    Prim Care; 1992 Mar; 19(1):87-96. PubMed ID: 1594704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?
    McKee AE; Markon AO; Chan-Tack KM; Lurie P
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S136-S142. PubMed ID: 28921646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits.
    Fountzilas E; Said R; Tsimberidou AM
    Expert Opin Investig Drugs; 2018 Feb; 27(2):155-162. PubMed ID: 29353505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ethical drug marketing criteria for the 21st century.
    Parker L; Williams J; Bero L
    BMJ; 2018 Apr; 361():k1809. PubMed ID: 29712644
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 2.